Zahra Mirzaie1, Ali Bastani2, Sepideh Hesami1, Elahe Pouryousefi1, Maria Kavianpour3, Hossein Khadem Haghighian4. 1. Department of Nutrition, School of Health, Qazvin University of Medical Sciences, Qazvin, Iran. 2. Department of Internal Medicine, Velayat Clinical Research Development Unit, Qazvin University of Medical Sciences, Qazvin, Iran. 3. Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran. 4. Department of Nutrition, School of Health, Qazvin University of Medical Sciences, Qazvin, Iran;Metabolic Diseases Research Center, Research Institute for Prevention of on-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran.
Abstract
BACKGROUND: The quality of sleep in people with irritable bowel syndrome (IBS) is reduced by increased oxidative stress and clinical problems. Assessing the effects of ellagic acid (EA) on sleep quality and gastrointestinal symptoms in patients with IBS was the aim of this study. METHODS: In this research that was conducted as a randomized, double-blind, placebo-controlled clinical trial, 44 patients with IBS were enlisted. Individuals approved by the project clinical counselor were divided into two intervention groups to receive 180 mg of EA per day (n = 22) and a placebo group (n = 22) for 2 months. Petersburg's Sleep Quality (PSQI) questionnaire and IBS severity score system (IBSSS) were assessed at the beginning and end of the study. Statistical analysis was performed using SPSS software. RESULTS: At the end of the study, changes in mean PSQI and scores related to sleep subgroups were significant between the two groups (P < .05). Also, the significant changes were not seen in sleep and sleep subgroups scores in the placebo group at the end of the study (P > .05). EA consumption reduced IBSSS score and IBS symptoms in the intervention group after 2 months (P < .05). DISCUSSION: The results arisen from this study indicated that receiving EA had a beneficial effect on sleep quality and gastrointestinal symptoms in IBS patients. The antioxidant and anti-inflammatory properties of EA may be responsible for these beneficial effects.
BACKGROUND: The quality of sleep in people with irritable bowel syndrome (IBS) is reduced by increased oxidative stress and clinical problems. Assessing the effects of ellagic acid (EA) on sleep quality and gastrointestinal symptoms in patients with IBS was the aim of this study. METHODS: In this research that was conducted as a randomized, double-blind, placebo-controlled clinical trial, 44 patients with IBS were enlisted. Individuals approved by the project clinical counselor were divided into two intervention groups to receive 180 mg of EA per day (n = 22) and a placebo group (n = 22) for 2 months. Petersburg's Sleep Quality (PSQI) questionnaire and IBS severity score system (IBSSS) were assessed at the beginning and end of the study. Statistical analysis was performed using SPSS software. RESULTS: At the end of the study, changes in mean PSQI and scores related to sleep subgroups were significant between the two groups (P < .05). Also, the significant changes were not seen in sleep and sleep subgroups scores in the placebo group at the end of the study (P > .05). EA consumption reduced IBSSS score and IBS symptoms in the intervention group after 2 months (P < .05). DISCUSSION: The results arisen from this study indicated that receiving EA had a beneficial effect on sleep quality and gastrointestinal symptoms in IBS patients. The antioxidant and anti-inflammatory properties of EA may be responsible for these beneficial effects.
Authors: A Patel; S Hasak; B Cassell; M A Ciorba; E E Vivio; M Kumar; C Prakash Gyawali; G S Sayuk Journal: Aliment Pharmacol Ther Date: 2016-05-30 Impact factor: 8.171
Authors: A Abbasnezhad; R Amani; E Hajiani; P Alavinejad; B Cheraghian; A Ghadiri Journal: Neurogastroenterol Motil Date: 2016-05-07 Impact factor: 3.598
Authors: Kendra J Kamp; Kristen R Weaver; LeeAnne B Sherwin; Pamela Barney; Sun-Kyung Hwang; Pei-Lin Yang; Robert L Burr; Kevin C Cain; Margaret M Heitkemper Journal: J Psychosom Res Date: 2019-08-29 Impact factor: 3.006